Alexion:
Atypical-HUS Email

This piece conveyed a complicated message regarding risk factors for atypical-HUS and the serious and potentially life-threatening consequences of discontinuing treatment with a C5 inhibitor, and in turn, highlights the ULTOMIRIS efficacy message. The piece also encourages readers to download a brochure for more information.

_______

Individualize treatment duration for atypical-HUS patients.

Atypical-HUS patients may be at continuous risk for life-threatening, complement-mediated thrombotic microangiopathy (TMA). Identify at-risk patients and individualize C5 inhibitor treatment plans.